Analyses focused on CML cell lines, primary cells, as well as mouse models, suggest that combined TKI treatment and EZH2 inhibition can delay leukemia development, extend survival and decrease the LSC burden through upregulation of H3K27me3 targets. This evidence concerns the gene EZH2 and leukemia.